These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [The immunotherapeutic approaches to the management of leukemia and neoplasms]. Leu TP Zhonghua Yi Xue Za Zhi; 1974 May; 5():310-4. PubMed ID: 4211699 [No Abstract] [Full Text] [Related]
3. [Current and prospective problems in tumor immunology]. Pitzurra M Boll Ist Sieroter Milan; 1971; 50(3):209-20. PubMed ID: 4947785 [No Abstract] [Full Text] [Related]
4. Strategies to overcome immune ignorance and tolerance. Perales MA; Blachere NE; Engelhorn ME; Ferrone CR; Gold JS; Gregor PD; Noffz G; Wolchok JD; Houghton AN Semin Cancer Biol; 2002 Feb; 12(1):63-71. PubMed ID: 11926414 [TBL] [Abstract][Full Text] [Related]
5. [Tumours and immunity. II. Special part. Tumour antigens. The immune response by neoplasms. Immunotherapy]. Ulvund MJ Nord Vet Med; 1972; 24(7):380-7. PubMed ID: 4666480 [No Abstract] [Full Text] [Related]
6. [Possibilities of the immunotherapy of cancer]. Tanaka S; Orita K Geka Chiryo; 1967 Nov; 17(5):522-8. PubMed ID: 4877443 [No Abstract] [Full Text] [Related]
7. Reversal of tumor-mediated immunosuppression. Vieweg J; Su Z; Dahm P; Kusmartsev S Clin Cancer Res; 2007 Jan; 13(2 Pt 2):727s-732s. PubMed ID: 17255301 [TBL] [Abstract][Full Text] [Related]
8. Determination of anti-malignin antibody and malignin in 1,026 cancer patients and controls: relation of antibody to survival. Bogoch S; Bogoch ES; Fager CA; Harris JH; Ambrus JL; Lux WE; Ransohoff JA J Med; 1982; 13(1-2):49-69. PubMed ID: 6750020 [No Abstract] [Full Text] [Related]
10. Cancer vaccines. Dalgleish AG Br J Cancer; 2000 May; 82(10):1619-24. PubMed ID: 10817493 [No Abstract] [Full Text] [Related]
11. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Mocellin S; Rossi CR; Nitti D Exp Cell Res; 2004 Oct; 299(2):267-78. PubMed ID: 15350526 [TBL] [Abstract][Full Text] [Related]
12. [Tumor immunology]. Mäkelä O Duodecim; 1969; 85(3):172-7. PubMed ID: 4893759 [No Abstract] [Full Text] [Related]
13. [Cancer therapy and the immune response of the body]. Bergol'ts VM Vopr Onkol; 1970; 16(12):82-93. PubMed ID: 4932064 [No Abstract] [Full Text] [Related]
14. Targets of protective tumor immunity. Dranoff G Ann N Y Acad Sci; 2009 Sep; 1174():74-80. PubMed ID: 19769739 [TBL] [Abstract][Full Text] [Related]
15. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. de Souza AP; Bonorino C Expert Rev Anticancer Ther; 2009 Sep; 9(9):1317-32. PubMed ID: 19761435 [TBL] [Abstract][Full Text] [Related]
17. Antigen-specific suppressor ("blocking") factors in tumor immunity. Hellström KE; Hellström I; Nelson K Biomembranes; 1983; 11():365-88. PubMed ID: 6219721 [No Abstract] [Full Text] [Related]
18. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Orentas RJ; Kohler ME; Johnson BD Semin Cancer Biol; 2006 Apr; 16(2):137-49. PubMed ID: 16376101 [TBL] [Abstract][Full Text] [Related]
19. Cancer vaccines: pessimism in check. Mocellin S; Mandruzzato S; Bronte V; Marincola FM Nat Med; 2004 Dec; 10(12):1278-9; author reply 1279-80. PubMed ID: 15580242 [No Abstract] [Full Text] [Related]